Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Wendtner CM, et al. Leukemia. 2004 Jun;18(6):1093-101. doi: 10.1038/sj.leu.2403354. Leukemia. 2004. PMID: 15071604 Clinical Trial.
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M. Elter T, et al. Among authors: wendtner cm. Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15. Leukemia. 2012. PMID: 22584787 Clinical Trial. No abstract available.
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, Kerwien S, Kuckertz M, Brinker R, Claasen J, Frenzel LP, Wendtner CM, Heider KH, Hallek M. Krause G, et al. Among authors: wendtner cm. Leukemia. 2012 Mar;26(3):546-9. doi: 10.1038/leu.2011.233. Epub 2011 Sep 2. Leukemia. 2012. PMID: 21886169 No abstract available.
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, Bergmann M, Staber PB, Porpaczy E, Einberger C, Heinz M, Hauswirth A, Raderer M, Pabinger I, Thalhammer R, Egle A, Wendtner CM, Follows G, Hoermann G, Quehenberger P, Jilma B, Jaeger U. Kazianka L, et al. Among authors: wendtner cm. Leukemia. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2. Leukemia. 2017. PMID: 27909342 Free PMC article.
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B. Maurer C, et al. Among authors: wendtner cm. Leukemia. 2016 Oct;30(10):2019-2025. doi: 10.1038/leu.2016.113. Epub 2016 May 2. Leukemia. 2016. PMID: 27133817 Clinical Trial.
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M. Fink AM, et al. Among authors: wendtner cm. Leukemia. 2013 Sep;27(9):1949-52. doi: 10.1038/leu.2013.190. Epub 2013 Jun 21. Leukemia. 2013. PMID: 23787395 Free PMC article. No abstract available.
226 results